Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: r. peter Dale who wrote (3040)	12/1/1997 11:03:00 AM
From: JOHN W.	Read Replies (1) of 6136

NOTE THAT AGOURON'S PROGRAM IS MANY YEARS AHEAD OF THIS COLLABORATION ON ANOTHER BLOCKBUSTER. THERE MUST BE A LARGE MKT FOR THIS HEP C INHIBITOR. , 9:24 am Eastern Time Bristol-Myers , Arris in pact PRINCETON, N.J., Dec 1 (Reuters) - Bristol-Myers Squibb Co said Monday that it has reached an agreement with Arris Pharmaceutical Corp to develop protease inhibitors to prevent the growth and spread of hepatitis C virus (HCV) infection. The hepatitis C protease is an enzyme that the virus needs to reproduce. Bristol-Myers Squibb will receive exclusive development and marketing rights to any HCV protease inhibitors produced in the collaboration. In return, Bristol-Myers will provide research funding as well as up-front, milestone, and royalty payments to Arris. Financial terms of the agreement were not disclosed. Arris will apply its proprietary Delta Technology to design potent and selective inhibitors of the protease enzyme of HCV.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next